{"id":"https://openalex.org/W4281553780","doi":"https://doi.org/10.1111/bjh.18284","title":"Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real\u2010world experience","display_name":"Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real\u2010world experience","publication_year":2022,"publication_date":"2022-05-25","ids":{"openalex":"https://openalex.org/W4281553780","doi":"https://doi.org/10.1111/bjh.18284","pmid":"https://pubmed.ncbi.nlm.nih.gov/35614565"},"language":"en","primary_location":{"id":"doi:10.1111/bjh.18284","doi":"https://doi.org/10.1111/bjh.18284","is_oa":false,"landing_page_url":"https://doi.org/10.1111/bjh.18284","pdf_url":null,"source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5002643270","display_name":"Naseema Gangat","orcid":"https://orcid.org/0000-0002-9104-6172","observed_orcids":["https://orcid.org/0000-0002-9104-6172"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Naseema Gangat","raw_affiliation_strings":["Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA"],"raw_orcid":"https://orcid.org/0000-0002-9104-6172","affiliations":[{"raw_affiliation_string":"Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076034488","display_name":"Kristen Beth McCullough","orcid":"https://orcid.org/0000-0003-4252-2619","observed_orcids":["https://orcid.org/0000-0003-4252-2619"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kristen McCullough","raw_affiliation_strings":["Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008422091","display_name":"Aref Al\u2010Kali","orcid":"https://orcid.org/0000-0002-0824-3715","observed_orcids":["https://orcid.org/0000-0002-0824-3715"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aref Al\u2010Kali","raw_affiliation_strings":["Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA"],"raw_orcid":"https://orcid.org/0000-0002-0824-3715","affiliations":[{"raw_affiliation_string":"Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080965667","display_name":"Kebede H. Begna","orcid":"https://orcid.org/0000-0003-2730-8593","observed_orcids":["https://orcid.org/0000-0003-2730-8593"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kebede H. Begna","raw_affiliation_strings":["Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072463255","display_name":"Mrinal M. Patnaik","orcid":"https://orcid.org/0000-0001-6998-662X","observed_orcids":["https://orcid.org/0000-0001-6998-662X"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mrinal M. Patnaik","raw_affiliation_strings":["Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085360755","display_name":"Mark Robert Litzow","orcid":"https://orcid.org/0000-0002-9816-6302","observed_orcids":["https://orcid.org/0000-0002-9816-6302"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark R. Litzow","raw_affiliation_strings":["Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084606047","display_name":"William J. Hogan","orcid":"https://orcid.org/0000-0002-5841-4105","observed_orcids":["https://orcid.org/0000-0002-5841-4105"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William Hogan","raw_affiliation_strings":["Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020872528","display_name":"Mithun Vinod Shah","orcid":"https://orcid.org/0000-0002-5359-336X","observed_orcids":["https://orcid.org/0000-0002-5359-336X"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mithun Shah","raw_affiliation_strings":["Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA"],"raw_orcid":"https://orcid.org/0000-0002-5359-336X","affiliations":[{"raw_affiliation_string":"Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064856519","display_name":"Hassan B. Alkhateeb","orcid":"https://orcid.org/0000-0002-3609-8404","observed_orcids":["https://orcid.org/0000-0002-3609-8404"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hassan Alkhateeb","raw_affiliation_strings":["Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012298768","display_name":"Abhishek Avinash Mangaonkar","orcid":"https://orcid.org/0000-0003-2458-9887","observed_orcids":["https://orcid.org/0000-0003-2458-9887"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Abhishek Mangaonkar","raw_affiliation_strings":["Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA"],"raw_orcid":"https://orcid.org/0000-0003-2458-9887","affiliations":[{"raw_affiliation_string":"Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035051206","display_name":"James M. Foran","orcid":"https://orcid.org/0000-0003-1673-1708","observed_orcids":["https://orcid.org/0000-0003-1673-1708"]},"institutions":[{"id":"https://openalex.org/I4210146710","display_name":"Mayo Clinic in Florida","ror":"https://ror.org/03zzw1w08","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210146710"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James M. Foran","raw_affiliation_strings":["Division of Hematology, Mayo Clinic, Jacksonville, Florida, USA"],"raw_orcid":"https://orcid.org/0000-0003-1673-1708","affiliations":[{"raw_affiliation_string":"Division of Hematology, Mayo Clinic, Jacksonville, Florida, USA","institution_ids":["https://openalex.org/I4210146710"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057941081","display_name":"Jeanne M. Palmer","orcid":"https://orcid.org/0000-0002-2185-1504","observed_orcids":["https://orcid.org/0000-0002-2185-1504"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]},{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeanne M. Palmer","raw_affiliation_strings":["Division of Hematology, Mayo Clinic, Scottsdale, Arizona, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, Mayo Clinic, Scottsdale, Arizona, USA","institution_ids":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024612499","display_name":"Animesh Dev Pardanani","orcid":"https://orcid.org/0000-0002-9084-4148","observed_orcids":["https://orcid.org/0000-0002-9084-4148"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Animesh Pardanani","raw_affiliation_strings":["Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA"],"raw_orcid":"https://orcid.org/0000-0002-9084-4148","affiliations":[{"raw_affiliation_string":"Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5016216479","display_name":"Ayalew Tefferi","orcid":"https://orcid.org/0000-0003-4605-3821","observed_orcids":["https://orcid.org/0000-0003-4605-3821"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Ayalew Tefferi","raw_affiliation_strings":["Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA"],"raw_orcid":"https://orcid.org/0000-0003-4605-3821","affiliations":[{"raw_affiliation_string":"Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA","institution_ids":["https://openalex.org/I1330342723"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5016216479"],"corresponding_institution_ids":["https://openalex.org/I1330342723"],"apc_list":{"value":4800,"currency":"USD","value_usd":4800},"apc_paid":null,"fwci":2.7952,"has_fulltext":false,"cited_by_count":19,"citation_normalized_percentile":{"value":0.91919125,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"198","issue":"4","first_page":"e54","last_page":"e58"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fedratinib","display_name":"fedratinib","score":1.0},{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.9829999804496765},{"id":"https://openalex.org/keywords/ruxolitinib","display_name":"ruxolitinib","score":0.9139999747276306},{"id":"https://openalex.org/keywords/relapsed-refractory-disease","display_name":"relapsed/refractory disease","score":0.9430000185966492},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.7900000214576721},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.6209999918937683},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.49900001287460327}],"concepts":[{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.9709322452545166},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.93760746717453},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.7740522623062134},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7428227066993713},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5366010665893555},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3260503113269806},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.10634550452232361},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000096926","descriptor_name":"Benzenesulfonamides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009570","descriptor_name":"Nitriles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011759","descriptor_name":"Pyrrolidines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055728","descriptor_name":"Primary Myelofibrosis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1111/bjh.18284","doi":"https://doi.org/10.1111/bjh.18284","is_oa":false,"landing_page_url":"https://doi.org/10.1111/bjh.18284","pdf_url":null,"source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},{"id":"pmid:35614565","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/35614565","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of haematology","raw_type":"Letter"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":14,"referenced_works":["https://openalex.org/W2008799537","https://openalex.org/W2010298229","https://openalex.org/W2161021913","https://openalex.org/W2339658711","https://openalex.org/W2405712018","https://openalex.org/W2801709198","https://openalex.org/W3009670005","https://openalex.org/W3105658552","https://openalex.org/W3184692155","https://openalex.org/W3200482254","https://openalex.org/W3211871096","https://openalex.org/W3213543135","https://openalex.org/W3213696764","https://openalex.org/W7074163837"],"related_works":["https://openalex.org/W3211871096","https://openalex.org/W2995010510","https://openalex.org/W4306639578","https://openalex.org/W4327900101","https://openalex.org/W3215427420","https://openalex.org/W4389248227","https://openalex.org/W4402479687","https://openalex.org/W3009670005","https://openalex.org/W3213696764","https://openalex.org/W2953787169"],"abstract_inverted_index":{"To":[0],"the":[1,57,65,91,148,154,160,231,264,282,333,358,374,616,662,700,786,854,948,983,1087,1359,1430,1486,1506,1510,1535,1548,1558,1576,1584,1605,1609,1616],"editor,":[2],"Fedratinib,":[3],"an":[4,142,200,1346,1541,1567],"oral":[5],"JAK2/FLT3":[6],"inhibitor":[7,74],"is":[8,1445,1467,1571],"FDA-approved":[9],"for":[10,26,103,124,344,435,1368],"myelofibrosis":[11],"(MF),":[12],"including":[13,288],"primary":[14,181],"MF":[15,96,173,193,217,260,396,805,1369,1551],"(PMF),":[16],"post-essential":[17],"thrombocythaemia":[18],"(post-ET":[19],"MF)":[20],"and":[21,28,41,45,80,86,105,110,127,206,241,258,273,292,295,302,339,369,508,587,604,633,671,768,819,826,887,1012,1019,1044,1075,1134,1166,1195,1214,1259,1280,1312,1390,1419,1488,1516,1566,1582,1603],"post-polycythaemia":[22],"vera":[23],"(post-PV":[24],"MF),":[25],"treatment-na\u00efve":[27],"relapsed/refractory":[29,195,218],"patients":[30,76,97,171,194,215,245,270,310,394,426,450,493,522,565,603,637,682,705,729,740,812,899,938,957,976,993,1014,1049,1070,1088,1183,1221,1270,1340,1370,1398,1438,1458,1481,1552],"following":[31,432,1237,1371,1402],"ruxolitinib":[32,36,99,197,220,290,433,455,475,495,503,513,526,533,677,685,712,731,742,1042,1072,1090,1372,1404,1414,1538],"failure.1":[33],"The":[34,210,1336,1353,1503],"high":[35,612,630,640],"discontinuation":[37,1497],"rate":[38],"of":[39,115,145,162,202,255,284,286,316,392,440,448,461,469,472,520,532,547,592,602,618,635,664,666,681,697,702,711,722,801,835,856,895,934,943,953,967,973,985,990,1005,1028,1055,1086,1231,1242,1266,1273,1282,1288,1322,1339,1349,1351,1363,1377,1436,1464,1480,1500,1505,1518,1522,1537,1550,1556,1608],"50":[40],"75%":[42,546],"at":[43,230,281,312,367,661,798,944,982,1277,1292,1374],"3":[44,49,67,470,817,866,1278],"5":[46,484],"years,":[47,416],"respectively,2,":[48],"poses":[50],"a":[51,227,436,467,708,718,799,831,1096,1228,1240,1391,1434],"therapeutic":[52,1361,1559],"dilemma":[53],"with":[54,70,77,98,166,172,176,190,216,224,271,318,361,395,423,490,684,699,707,909,977,1000,1024,1052,1099,1118,1156,1162,1341,1447,1461,1478,1492],"fedratinib":[55,71,116,163,191,225,287,619,1157,1163,1238,1364,1401,1533,1562],"as":[56,459,606,1365],"only":[58,951],"FDA":[59,132],"approved":[60,1604],"salvage":[61,1366],"therapy.1,":[62],"4":[63],"In":[64,518,1148,1318,1407],"Phase":[66,149],"JAKARTA":[68],"study":[69,93,152,212,1355],"in":[72,90,119,136,147,164,170,192,349,363,545,550,553,557,563,568,572,576,580,584,589,600,631,728,810,845,853,880,884,914,971,1048,1123,1127,1138,1142,1180,1193,1202,1301,1457,1495,1498,1520,1543,1547],"JAK":[73],"na\u00efve":[75],"MF,":[78,403,409],"spleen":[79,104,703,721,901,910,998,1036,1097,1103,1114,1420],"symptom":[81,106,920,924,940,996,1452],"response":[82,107,462,668,902,960,963,999,1004,1016,1026,1037,1057,1098,1108,1115,1421,1453,1523],"rates":[83,102,1058],"were":[84,108,246,277,307,378,427,452,524,598,638,747,843,1059,1222,1245,1384,1416],"47":[85],"40%,":[87],"respectively.5":[88],"Similarly,":[89],"JAKARTA-2":[92],"which":[94,198,456,903,1184,1395,1427,1444],"included":[95,543,561,1185,1396],"failure,":[100],"corresponding":[101,1617],"31":[109],"27%.6":[111],"Historically,":[112],"clinical":[113,228,656,1387],"development":[114],"was":[117,134,183,261,329,347,355,457,478,534,629,782,796,904,969,1038,1045,1116,1178,1200,1422,1454,1475],"halted":[118],"2013":[120],"due":[121,849,1207,1247],"to":[122,158,184,196,219,332,454,485,750,850,931,1003,1188,1208,1224,1248,1386,1468,1530,1532],"concern":[123],"Wernicke's":[125],"encephalopathy,":[126],"after":[128,249,466,804],"subsequent":[129],"safety":[130,140],"analysis,":[131],"approval":[133,188],"obtained":[135],"August":[137,239],"2019.":[138],"Accordingly,":[139],"remains":[141],"ongoing":[143],"focus":[144],"investigation":[146],"3b":[150],"FREEDOM":[151],"while":[153,777,814,1175,1219],"FREEDOM2":[155],"trial":[156,229,1388],"seeks":[157],"evaluate":[159],"efficacy":[161,1490],"comparison":[165,680],"best":[167],"available":[168],"therapy":[169,434,1177,1323,1367],"previously":[174,1050,1459],"treated":[175,683,706,1051,1460,1501],"ruxolitinib.7,":[177],"8":[178,836],"Herein,":[179],"our":[180,186,1437],"objective":[182],"describe":[185],"post-FDA":[187],"experience":[189],"includes":[199,213],"assessment":[201,921,1348],"its":[203,1128,1143],"efficacy,":[204],"toxicity,":[205],"impact":[207,1107,1331],"on":[208,322,512,525,730,741,906,1071,1089,1176,1358,1412],"survival.":[209,1352],"current":[211,1354,1507],"28":[214,393],"that":[221,523,1408,1471,1528],"received":[222,311,421,823,1400],"treatment":[223,422,438,476,833,986,1496],"outside":[226],"Mayo":[232],"Clinic":[233],"(Rochester":[234],"MN,":[235],"Arizona,":[236],"Florida)":[237],"between":[238,785],"2019":[240],"November":[242],"2021.":[243],"Study":[244],"retrospectively":[247],"recruited":[248],"institutional":[250],"review":[251],"board":[252],"approval.":[253],"Diagnosis":[254],"PMF,":[256],"post-ET":[257],"post-PV":[259],"established":[262],"by":[263,299,357,373,536,642,675,961,1017,1040,1424],"World":[265],"Health":[266],"Organization":[267],"2016":[268],"criteria;9":[269],"accelerated":[272,1189],"blast":[274,1191],"phase":[275,1192],"disease":[276,464,659,1186,1209,1250],"excluded.":[278],"Clinical":[279],"details":[280,1411],"time":[283,617,663,984,1002],"initiation":[285,665],"prior":[289,676,1041,1403,1413,1448,1529],"dose":[291,319,477,710,841,1043,1158,1415,1483,1536],"duration,":[293],"cytogenetic":[294],"molecular":[296],"studies":[297,908],"performed":[298,379,1580],"conventional":[300],"karyotype,":[301],"next-generation":[303],"sequencing":[304],"(NGS),":[305],"respectively,":[306,1023],"abstracted.":[308],"All":[309,425,1600],"least":[313,945],"one":[314,585,590,820,885,952,1196],"cycle":[315],"fedratinib,":[317,667,1443],"adjusted":[320],"based":[321],"toxicity":[323,670,852,1215,1474,1493],"per":[324],"treating":[325],"physician":[326],"discretion.":[327],"Response":[328],"assessed":[330,1423],"according":[331],"International":[334],"Working":[335],"Group-Myeloproliferative":[336],"Neoplasms":[337],"Research":[338],"Treatment":[340,1199],"(IWG-MRT)":[341],"criteria.10":[342],"Follow-up":[343],"each":[345],"patient":[346,822,1197],"updated":[348],"February":[350],"2022.":[351],"Overall":[352],"survival":[353,1303,1332],"post-fedratinib":[354,1302,1343],"evaluated":[356],"Kaplan\u2013Meier":[359],"method":[360],"differences":[362],"responders":[364,1285,1306],"versus":[365,688,725,1064,1271,1286,1307,1326],"non-responders":[366,1276,1291,1308],"3-":[368,1018],"6-months":[370,1020],"post-therapy":[371,1295],"compared":[372],"log-rank":[375],"test.":[376],"Analyses":[377],"using":[380],"JMP":[381],"Pro":[382],"16.0.0":[383],"software":[384],"package,":[385],"SAS":[386],"Institute,":[387],"Cary,":[388],"NC.":[389],"A":[390,446,679,988],"total":[391,447,923,989,1241],"(PMF,":[397],"n":[398,404,410,509],"=":[399,405,411,501,510,737,759,766,775,790,862,869,876,891,1062,1067,1082,1110,1132,1146,1171,1212,1217,1252,1257,1263,1310,1314,1334],"11,":[400],"post":[401,407,1021],"PV":[402],"12,":[406],"ET":[408],"5,":[412],"median":[413,437,719,800,832,1001,1025,1229],"age":[414],"73":[415],"range":[417],"52\u201385;":[418],"54%":[419],"females)":[420],"fedratinib.":[424],"either":[428,607,995],"relapsed":[429],"or":[430,463,610,1190],"refractory":[431,453],"duration":[439,834,1027,1321],"18":[441,449],"months":[442,471,837,1007,1030,1233,1294,1325,1328],"(range;":[443,483,807,1008,1031,1234],"3\u201362":[444],"months).":[445,1010,1033],"(64%)":[451],"defined":[458],"lack":[460,1517],"progression":[465,1174,1210],"minimum":[468],"therapy.":[473],"Median":[474],"15":[479,846,1203],"mg":[480,487,497,505,515,528,687,691,714,733,744,794,1074,1077,1092,1165,1168,1379],"twice":[481,488,498,506,516,529,692,715,734,745,1078,1093,1380],"daily":[482,499,507,693,716,735,746,795,1094],"25":[486,514,935],"daily)":[489],"11":[491],"(39%)":[492],"receiving":[494],"\u226520":[496,686,713,743,1073,1091,1378],"(n":[500,861,868,875,890,1061,1066,1211,1216,1251,1256,1262],"9,":[502],"20":[504,593,690,811,930],"2":[511],"daily).":[517],"12":[519],"17":[521],"<20":[527,732,1076],"daily,":[530,1079,1169],"uptitration":[531],"limited":[535,1342,1360,1487],"anaemia":[537,867,959],"and/or":[538,859,997,1035,1113],"thrombocytopenia.":[539],"Driver":[540],"mutation":[541,643],"profile":[542],"JAK2":[544],"patients,":[548,848,1205],"CALR":[549],"18%,":[551],"MPL":[552],"4%,":[554,558],"triple":[555],"negative":[556],"other":[559,949],"mutations":[560,770,1136],"ASXL1":[562],"eight":[564,933],"(40%),":[566],"TET2":[567],"four":[569,573,815],"(20%),":[570,574],"NRAS":[571,769,1135],"SRSF2":[575],"three":[577],"(15%),":[578],"U2AF1":[579,761],"two":[581,787,915,972,1194,1220,1281],"(10%),":[582],"EZH2":[583],"(5%)":[586,591],"TP53":[588],"informative":[594],"cases.":[595,916],"Cytogenetic":[596],"abnormalities":[597],"present":[599],"74%":[601],"classified":[605],"unfavourable":[608],"(30%)":[609],"very":[611],"risk":[613,627,641,753,780],"(5%).":[614],"At":[615,830,1227],"initiation,":[620],"dynamic":[621],"international":[622,645],"prognostic":[623,646],"scoring":[624,647],"system":[625,648],"(DIPSS)":[626],"distribution":[628,781],"43%,11":[632],"69%":[634],"evaluable":[636,898],"high/very":[639],"enhanced":[644],"version":[649],"2.0":[650],"(MIPSS":[651],"v2).12":[652],"Table":[653],"1":[654],"provides":[655],"information":[657],"regarding":[658],"characteristics":[660],"rates,":[669],"overall":[672],"outcome":[673],"stratified":[674],"dose.":[678],"<":[689],"illustrates":[694],"no":[695],"evidence":[696],"difference":[698,1300],"exception":[701],"size;":[704],"higher":[709,1053,1375,1462,1554],"had":[717,1296],"pretreatment":[720,1102],"29.7":[723],"cm":[724,727],"22.1":[726],"(p":[736,789,1081,1109,1309,1333],"0.05).":[738],"Moreover,":[739,1485],"more":[748],"likely":[749,1047,1456],"harbour":[751],"unfavourable/high":[752],"karyotype":[754,1121],"(45%":[755],"vs.":[756,763,772,1125,1140,1160],"13%,":[757],"p":[758,765,774,1131,1145,1170,1313],"0.05),":[760],"(25%":[762,1137],"0%,":[764],"0.04),":[767],"(38%":[771],"8%,":[773],"0.11)":[776],"MIPSS":[778],"v2":[779],"not":[783,1106,1152,1330,1417,1476],"different":[784],"groups":[788],"0.59).":[791],"Fedratinib":[792],"400":[793,1164],"initiated":[797],"4.8":[802],"years":[803],"diagnosis":[806],"0.2\u201325":[808],"years)":[809],"(71%),":[813],"(14%),":[816],"(11%)":[818],"(4%)":[821],"300,":[824],"200":[825],"100":[827],"mg,":[828],"respectively.":[829],"(range,":[838],"1\u201329":[839],"months),":[840],"reductions":[842],"instituted":[844],"(54%)":[847,1204],"gastrointestinal":[851],"form":[855,922],"nausea,":[857],"vomiting":[858],"diarrhoea":[860],"6,":[863,877],"21%),":[864],"grade":[865,872],"7,":[870],"25%),":[871],"3/4":[873],"thrombocytopenia":[874],"21%)":[878],"resulting":[879],"fatal":[881],"subdural":[882,1260],"haematoma":[883,1261],"patient,":[886],"renal":[888],"insufficiency":[889],"4,":[892],"14%).":[893],"Three":[894],"24":[896],"(13%)":[897],"demonstrated":[900,939,994,1095],"confirmed":[905],"imaging":[907],"volume":[911],"reduction":[912,942],">35%":[913],"Baseline":[917],"myeloproliferative":[918],"neoplasm":[919],"score":[925,941],"(MPN-SAF":[926],"TSS)":[927],"ranged":[928],"from":[929,1442,1561],"70;":[932],"(32%)":[936,1275],"symptomatic":[937,1440],"50%.":[946],"On":[947],"hand,":[950],"14":[954,974],"(7%)":[955],"transfusion-dependent":[956],"achieved":[958,1015],"IWG-MRT":[962],"criteria;":[964],"moreover,":[965,1101],"resolution":[966],"leukocytosis":[968,978],"noted":[970],"(14%)":[975],">11":[979],"x":[980],"109/l":[981],"initiation.":[987],"10":[991],"(36%)":[992],"2.5":[1006],"1\u20137.4":[1009],"Six":[1011],"nine":[1013,1243,1283],"therapy,":[1022,1239],"7.8":[1029],"0\u201326":[1032],"Symptom":[1034,1112],"impacted":[1039],"less":[1046,1455],"doses":[1054,1376,1463,1555],"ruxolitinib;":[1056],"9%":[1060],"1)":[1063],"53%":[1065],"9)":[1068],"among":[1069,1304],"respectively":[1080],"0.01).":[1083],"Notably,":[1084],"none":[1085],"fedratinib;":[1100],"size":[1104],"did":[1105,1151,1329],"0.48).":[1111,1147],"similar":[1117],"unfavourable/very":[1119],"high-risk":[1120],"(29%":[1122],"presence":[1124,1139],"35%":[1126],"absence":[1129],"%;":[1130],"0.75)":[1133],"44%":[1141],"absence;":[1144],"addition,":[1149,1319],"responses":[1150,1383],"show":[1153],"significant":[1154,1299],"correlation":[1155],"(40%":[1159],"25%":[1161],"<400":[1167],"0.45).":[1172],"Disease":[1173],"documented":[1179],"seven":[1181,1272,1287],"(25%)":[1182],"transformation":[1187],"each.":[1198],"discontinued":[1201],"primarily":[1206],"7),":[1213],"6)":[1218],"bridged":[1223],"allogeneic":[1225],"transplant.":[1226],"follow-up":[1230,1344],"11.1":[1232],"1\u201329.1":[1235],"months)":[1236],"deaths":[1244],"recorded":[1246],"progressive":[1249],"6),":[1253],"infectious":[1254],"complications":[1255],"2),":[1258],"1).":[1264],"Two":[1265],"six":[1267],"(33%)":[1268],"responding":[1269],"22":[1274],"months,":[1279],"(22%)":[1284],"19":[1289],"(37%)":[1290],"6":[1293,1450],"died":[1297],"without":[1298],"symptom/spleen":[1305],"0.82":[1311],"0.46)":[1315],"(Figure":[1316],"1A,B).":[1317],"longer":[1320],"\u22656":[1324],"<6":[1327],"0.30).":[1335],"small":[1337,1513],"number":[1338],"precluded":[1345],"accurate":[1347],"predictors":[1350],"sheds":[1356],"light":[1357],"value":[1362,1560],"failure":[1373],"daily.":[1381],"Spleen":[1382],"inferior":[1385],"results":[1389],"recent":[1392],"real-world":[1393],"series":[1394],"150":[1397],"who":[1399],"failure.6,":[1405],"13":[1406],"particular":[1409],"study,":[1410,1577],"provided":[1418],"palpation":[1425],"alone":[1426],"might":[1428,1539,1563],"explain":[1429],"discrepant":[1431],"findings.":[1432],"Conversely,":[1433],"third":[1435],"derived":[1439],"benefit":[1441],"consistent":[1446],"observations;5,":[1449],"however,":[1451],"ruxolitinib.":[1465],"It":[1466],"be":[1469,1540,1564],"underscored":[1470],"drug":[1472],"related":[1473],"trivial":[1477],"half":[1479,1499],"requiring":[1482],"reductions.":[1484],"short-lived":[1489],"coupled":[1491],"resulted":[1494],"patients.":[1502,1545,1599],"limitations":[1504],"report":[1508],"include":[1509],"retrospective":[1511],"design,":[1512],"sample":[1514],"size,":[1515],"uniformity":[1519],"timing":[1521],"assessments.":[1524],"Our":[1525],"observations":[1526],"suggest":[1527],"switching":[1531],"increasing":[1534],"option":[1542],"select":[1544],"Regardless,":[1546],"instance":[1549],"failing":[1553],"ruxolitinib,":[1557],"minimal":[1565],"alternative":[1568],"management":[1569],"approach":[1570],"advised.":[1572],"NG,":[1573],"AT":[1574],"designed":[1575],"collected":[1578],"data,":[1579],"analysis":[1581],"cowrote":[1583],"manuscript.":[1585,1610],"KM,":[1586],"AA,":[1587],"KHB,":[1588],"MMP,":[1589],"MRL,":[1590],"WH,":[1591],"MS,":[1592],"HA,":[1593],"AM,":[1594],"JMF,":[1595],"JMP,":[1596],"AP":[1597],"contributed":[1598],"authors":[1601],"reviewed":[1602],"final":[1606],"draft":[1607],"No":[1611],"relevant":[1612],"conflicts.":[1613],"Please":[1614],"email":[1615],"author.":[1618]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":9},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-05-27T00:00:00"}